Prognostic factors by Cox proportional hazard regression
| Factor | Univariate analysis | Multivariate analysis | ||||||
| OS | PFS | OS | PFS | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Race (black vs others) | 1.22 (0.558 to 2.667) | 0.619 | 1.109 (0.439 to 2.804) | 0.826 | ||||
| Cell type (squamous cell carcinoma vs others) | 1.51 (0.475 to 4.802) | 0.485 | 0.388 (0.165 to 0.913) | 0.03 | ||||
| Tumor degree (3 vs 1 and 2) | 1.109 (0.637 to 1.93) | 0.716 | 1.241 (0.644 to 2.389) | 0.519 | ||||
| Tumor size | 1.085 (0.988 to 1.192) | 0.088 | 1.127 (1.016 to 1.249) | 0.023 | 1.145 (1.023 to 1.281) | 0.019 | 1.180 (1.050 to 1.326) | 0.006 |
| Pelvic lymphadenopathy (yes vs no) | 1.536 (0.926 to 2.55) | 0.097 | 2.257 (1.173 to 4.34) | 0.015 | 1.918 (1.071 to 3.436) | 0.029 | 2.203 (1.089 to 4.456) | 0.028 |
| Hydronephrosis (yes vs no) | 2.253 (1.336 to 3.799) | 0.002 | 0.958 (0.541 to 1.694) | 0.882 | 2.063 (1.121 to 3.795) | 0.02 | NS | |
| Creatinine clearance | 0.995 (0.988 to 1.002) | 0.177 | 1.003 (0.995 to 1.012) | 0.431 | ||||
| Concurrent chemoradiotherapy (yes vs no) | 0.315 (0.181 to 0.547) | <0.001 | 1.178 (0.5 to 2.774) | 0.707 | 0.43 (0.212 to 0.873) | 0.019 | NS | |
HR, hazard ratio; NS, not significant; OS, overall survival; PFS, progression-free survival.